动脉粥样硬化(AS)是心血管疾病的病理基础，口腔与肠道通过菌群移位、代谢互作及免疫联动共同构成口腔-肠道微生物轴，其稳态失衡通过菌群易位、代谢紊乱和屏障损伤等促进AS发生发展。中医药以整体观念与辨证论治为指导，多靶点调控口腔-肠道微生物平衡，抑制血管炎症与脂质沉积，发挥抗AS效应。本文系统阐述口腔-肠道微生物与AS的关联，探讨中医药调控微生态防治该病的研究进展，分析当前研究存在的局限并展望未来方向，为中医药防治AS提供新的思路与理论依据。
Atherosclerosis (AS) is the pathological basis of cardiovascular diseases. The oral cavity and the gut together constitute the oral-gut microbial axis through microbial translocation, metabolic interactions, and immune crosstalk. Dysbiosis of this axis promotes the occurrence and development of AS via bacterial translocation, metabolic disorders, and barrier damage. Guided by the holistic concept and syndrome differentiation-based treatment, traditional Chinese medicine (TCM) exerts anti-AS effects by multi-target regulation of the oral-gut microbial balance, inhibiting vascular inflammation and lipid deposition. This article systematically elaborates the association between the oral-gut microbiota and AS, explores the research progress of TCM in modulating microecology for the prevention and treatment of AS, analyzes the limitations of current studies, and prospects future directions, so as to provide new insights and theoretical basis for TCM in preventing and treating AS.
扩张型心肌病（DCM）以左心室或双心室扩大并伴心肌收缩功能下降为主要特征，左心室逆重构（LVRR）可反映治疗后心室结构和功能恢复，并与患者预后改善相关。近年来，中医药联合常规西医治疗DCM的研究逐渐增多，部分研究显示其可改善左心室射血分数、左心室内径或容积、BNP或NT-proBNP、6min步行距离及生活质量等LVRR相关指标。现有证据提示，中医药可能通过改善心肌细胞损伤与能量代谢、减轻心肌纤维化与细胞外基质重塑、调节神经内分泌激活与心室负荷等环节参与DCM患者左心室结构重塑改善和收缩功能恢复，从而促进LVRR。然而，现有研究对LVRR的判定标准尚未统一，相关临床证据仍需进一步规范和验证。鉴于此，本文旨在围绕DCM-LVRR的概念、评价指标、中医药临床证据及可能机制进行叙述性综述，以期为DCM的中西医结合治疗及后续临床研究设计提供参考。
Dilated cardiomyopathy (DCM) is mainly characterized by left ventricular or biventricular dilatation accompanied by impaired myocardial systolic function. Left ventricular reverse remodeling (LVRR) reflects the recovery of ventricular structure and function after treatment and is associated with improved prognosis. In recent years, studies on traditional Chinese medicine (TCM) combined with conventional Western medical therapy for DCM have gradually increased. Some studies have shown that such combined treatment may improve LVRR-related indicators, including left ventricular ejection fraction, left ventricular diameter or volume, BNP or NT-proBNP, 6-minute walking distance, and quality of life. Current evidence suggests that TCM may contribute to left ventricular structural remodeling and systolic functional recovery in patients with DCM by alleviating myocardial cell injury, improving energy metabolism, attenuating myocardial fibrosis and extracellular matrix remodeling, and modulating neuroendocrine activation and ventricular load, thereby promoting LVRR. However, the criteria for defining LVRR remain inconsistent across existing studies, and the relevant clinical evidence requires further standardization and validation. Therefore, this narrative review aims to summarize the concept, evaluation indicators, clinical evidence of TCM, and potential mechanisms related to DCM-LVRR, with the aim of providing a reference for integrated Chinese and Western medical treatment of DCM and the design of future clinical studies.
扩张型心肌病（DCM）以左心室或双心室扩大并伴心肌收缩功能下降为主要特征，左心室逆重构（LVRR）可反映治疗后心室结构和功能恢复，并与患者预后改善相关。近年来，中医药联合常规西医治疗DCM的研究逐渐增多，部分研究显示其可改善左心室射血分数、左心室内径或容积、BNP或NT-proBNP、6min步行距离及生活质量等LVRR相关指标。现有证据提示，中医药可能通过改善心肌细胞损伤与能量代谢、减轻心肌纤维化与细胞外基质重塑、调节神经内分泌激活与心室负荷等环节参与DCM患者左心室结构重塑改善和收缩功能恢复，从而促进LVRR。然而，现有研究对LVRR的判定标准尚未统一，相关临床证据仍需进一步规范和验证。鉴于此，本文旨在围绕DCM-LVRR的概念、评价指标、中医药临床证据及可能机制进行叙述性综述，以期为DCM的中西医结合治疗及后续临床研究设计提供参考。
Dilated cardiomyopathy (DCM) is mainly characterized by left ventricular or biventricular dilatation accompanied by impaired myocardial systolic function. Left ventricular reverse remodeling (LVRR) reflects the recovery of ventricular structure and function after treatment and is associated with improved prognosis. In recent years, studies on traditional Chinese medicine (TCM) combined with conventional Western medical therapy for DCM have gradually increased. Some studies have shown that such combined treatment may improve LVRR-related indicators, including left ventricular ejection fraction, left ventricular diameter or volume, BNP or NT-proBNP, 6-minute walking distance, and quality of life. Current evidence suggests that TCM may contribute to left ventricular structural remodeling and systolic functional recovery in patients with DCM by alleviating myocardial cell injury, improving energy metabolism, attenuating myocardial fibrosis and extracellular matrix remodeling, and modulating neuroendocrine activation and ventricular load, thereby promoting LVRR. However, the criteria for defining LVRR remain inconsistent across existing studies, and the relevant clinical evidence requires further standardization and validation. Therefore, this narrative review aims to summarize the concept, evaluation indicators, clinical evidence of TCM, and potential mechanisms related to DCM-LVRR, with the aim of providing a reference for integrated Chinese and Western medical treatment of DCM and the design of future clinical studies.
动脉粥样硬化（AS）是一种起始于炎症介导的内皮损伤的慢性血管疾病，其本质是免疫炎症驱动的病理过程，是众多心血管疾病的病理基础。CD4+ T细胞亚群［包括辅助性T细胞1型（T helper 1 cell，Th1）、Th2、Th17、调节性T细胞等］通过分泌特异性细胞因子参与AS的炎症反应，其中促炎性CD4+ T细胞与抗炎性CD4+ T细胞的抗炎功能失衡是推动斑块进展的关键环节，在AS斑块形成与发展中起关键作用。近年来，多项研究表明某些中药单体、经典复方及其有效成分，具有多靶点、多层次机制调控CD4+ T细胞分化及功能，这些作用共同减轻血管内皮炎症反应、抑制巨噬细胞泡沫化及平滑肌细胞迁移等，延缓AS斑块形成与发展，为AS防治提供了新思路，展现了中医药在该领域的研究展现出独特优势与广阔前景，本文综述了中医药通过干预CD4+ T细胞亚群平衡防治AS的最新研究进展，及其影响相关细胞因子网络及关键信号通路的作用机制，为开发具有多靶点协同优势的创新中药与中西医结合治疗方案提供了关键理论依据与实践方向。
Atherosclerosis（AS）is a chronic vascular disease that originates from inflammation mediated endothelialdamage．Its essence is a pathological process driven by immune inflammation，and it is the pathological basis of many cardiovascular diseases．CD4+ T cell subsets（including Th1，Th2，Th17，Treg，etc.）participate in the inflammatory response of AS by secreting specific cytokines．The imbalance of anti-inflammatory function between pro-inflammatory CD4+ T cells and anti-inflammatory CD4+T cells is a key link in promoting plaque progression and playing a crucial role in the formation and development of AS plaques．In recent years，a number of studies have shown that the monomers，classic prescriptions and their effective ingredients of Chinese herbs have the effect of multi-target，multi-level mechanism to regulate the differentiation and function of CD4+ T cells．These effects together reduce the inflammatory reaction of vascular endothelium，inhibit the foam formation of macrophages and smooth muscle cell migration，delay the formation and development of AS plaque，provide new ideas for the prevention and treatment of AS，and make the research of Chinese medicine show unique advantages and broad prospects in this field．This article reviews the latest research progress of Chinese medicine in the prevention and treatment of AS by intervening in the balance of CD4+ T cell subsets，as well as the mechanism of its effects on related cytokine networks and key signal pathways．This provides a key theoretical basis and practical direction for the development of innovative traditional Chinese medicine and integrated traditional Chinese and Western medicine treatment plans with multi-target synergistic advantages．
目的 剖析中医药治疗儿童哮喘的随机对照试验（RCT）结局指标，为中医药治疗该病临床试验的核心指标集构建提供初步依据。方法 检索中国知网（CNKI）、万方（WanFang）、维普网（VIP）、中国生物医学文献数据库（SinoMed）、PubMed、Cochrane Library、EmBase、Web of Science。时间跨度为建库至2024年7月1日。此次检索全面覆盖了中医药疗法治疗儿童哮喘的临床随机对照研究，由两名研究者根据纳排标准独立完成文献筛选和资料提取，提取文献基本特征和结局指标。结果 初步检索出2 449篇文献，最终纳入165个RCT，包括205个结局指标，分为症状/体征、中医症状/证候、理化检查、生活质量评价、远期预后、安全性指标六域。结论 中医药治疗儿童哮喘尚存在中医证候诊断和疗效标准不完善、主要和次要结局指标界限不清等问题，应当构建统一规范且广为认可的核心指标集，以促进儿童哮喘核心指标集的完善。
Objective To analyze the outcome indicators of randomised controlled trials（RCTs）of traditional Chinese medicine（TCM）for the treatment of childhood asthma，and to provide a preliminary basis for the construction of a core set of indicators for clinical trials of TCM for the treatment of this disease．Methods A database search was conducted on China Knowledge Network（CNKI），WanFang，VIP，SinoMed，PubMed，Cochrane Library，EmBase，and Web of Science，covering the period from the establishment of the database to 1 July 2024．The search comprehensively covered clinical randomised controlled studies of TCM therapies in the treatment of childhood asthma，and was completed independently by two investigators who screened the literature and extracted information according to the criteria，and extracted the basic characteristics of the literature and outcome indicators．Results Initially，2 449 literatures were retrieved，and 165 RCTs were finally included，including 205 outcome indicators，which were classified into six domains：symptoms/signs，TCM symptoms/evidence，physical and chemical examination，quality of life evaluation，long-term prognosis，and safety indicators．Conclusions Currently，there are problems such as imperfect diagnostic and efficacy criteria for TCM evidence，and unclear boundaries between primary and secondary outcome indicators in the treatment of childhood asthma with TCM．A unified，standardised and widely recognised core indicator set should be constructed to promote the improvement of the core indicator set for childhood asthma．
目的 探讨中医药治疗小儿腺样体肥大（AH）的研究现状、研究热点及趋势,为本领域研究者提供借鉴。方法 检索中国知网（CNKI）数据库从2005年1月1日至2024年1月31日中医药治疗小儿腺样体肥大的相关文献。运用Excel 2019分析其发文量,运用CiteSpace 6.2.R6软件分析其作者、机构、关键词。结果 共纳入文献395篇,年发文量整体呈现波动上升的趋势;发文量最多的作者为姜之炎;发文量最多的研究机构为山东中医药大学。初步形成了以姜之炎、俞景茂、阎兆君为核心的研究团队;研究机构以中医类院校及其附属医院为主。高频关键词提示当前研究热点前三位为中医药治疗方法、临床疗效。结论 AH领域研究内容主要以内治法、外治法、作用机制为主;研究热点逐渐从临床研究转向作用机制等实验研究;应用“数据挖掘”“网络药理学”等计算机技术研究AH会成为趋势。
Objective To explore the research status,research hotspots,and trends of traditional Chinese medicine in the treatment of adenoid hypertrophy in children,to provide a reference for researchers in this field．Methods The relevant literature on the treatment of adenoid hypertrophy in children with traditional Chinese medicine was searched in the CNKI database from January 1,2005,to January 31,2024．Excel 2019 was applied to analyze the number of published papers,and CiteSpace 6.2.R6 software was applied to analyze its authors,institutions,and keywords．Results A total of 395 papers were included,and the annual number of papers showed a fluctuating upward trend．The author with the largest number of papers was JIANG Zhiyan．Shandong University of Traditional Chinese Medicine was the research institution with the largest number of papers．The core research teams including JIANG Zhiyan,YU Jingmao,and YAN Zhaojun were initially formed．The research institutions were mainly Chinese medicine colleges and their affiliated hospitals．High-frequency keywords suggest that the current top three research hotspots were traditional Chinese medicine treatment methods,clinical efficacy．Conclusions The research content in this field is mainly based on internal treatment,external treatment,and mechanism．The focus has gradually shifted from clinical research to experimental research such as mechanism．The application of computer technologies such as “data mining” and “network pharmacology” for this disease will become a trend．
慢性萎缩性胃炎是常见的胃癌前病变,不仅治疗过程漫长,治疗难度大,而且患者依从性欠佳。不仅会对患者的生理、心理健康和生活质量造成严重不良的影响,还会给患者家属造成负担,成为临床上不可忽视的难题。但是本病发病机制目前尚未完全明确,临床治疗还未达成共识。文章综述了近10年基于Hedgehog信号通路的中医药干预慢性萎缩性胃炎的研究概况。中医药调控Hedgehog信号通路辨证论治是治疗慢性萎缩性胃炎的一种独具特色的疗法,近年来有关基于Hedgehog信号通路的中医药干预治疗慢性萎缩性胃炎的报道越来越多。文章主要通过遵循疾病本虚标实的病性,以脾胃虚弱为本,瘀血、气滞、湿热、痰浊等为标,探讨选方治疗对慢性萎缩性胃炎的影响,认为中医药联合Hedgehog信号通路实行现代化发展能够有效干预治疗慢性萎缩性胃炎,以期为进一步临床研究与应用提供参考。
Chronic atrophic gastritis,a common precancerous lesion of gastric cancer,requires a long-term treatment and is difficult to cure．Therefore,it usually leads to decreased patient compliance．It will not only have a serious adverse impact on the patient’s physical and mental health and quality of life,but also cause a burden to the patient’s family,which has become a difficult problem that can not be ignored clinically．However,the pathogenesis has not yet been totally clarified,not to mention a consensus on the clinical treatment．This paper reviews the research revolving around Chinese medicine intervention in chronic atrophic gastritis based on the Hedgehog signaling pathway in the last decade．It’s creative therapy of chronic atrophic gastritis that utilizing Traditional Chinese Medicine to regulate and control Hedgehog signaling pathway,which has been increasingly reported in recent years．This paper is based on “deficiency in origin” and “excess in superficiality” principle．Concretely,spleen-stomach vacuity is characterized by deficiency in origin,and excess in superficiality manifests blood stasis,qi stagnation,dampness-heat and phlegm turbidity as excess in superficiality．By this way,the paper explores the effect of prescription selection on chronic atrophic gastritis．It is believed that the modern therapy that combines traditional Chinese medicine with Hedgehog signaling pathway can tackle chronic atrophic gastritis,thus providing a reference for further clinical trials and practices．
目的 探究中医药治疗盆腔炎的用药规律,为中医临床辩证用药提供借鉴。方法 采用主题词联合自由词相,全面检索CNKI、VIP、Wangfang、CBM、PubMed和EMbase、数据库及Cochrane图书馆,收集中、西药对比治疗盆腔炎的随机对照试验。严格按照纳入、排除标准挑选随机对照试验中涵盖的中药药方,采用Excel表格统计分析药方中药的四气、五味、归经和用药频率,随后利用系统聚类软件对使用频率高的中药开展关联、聚类和主成分分析。结果 本文共纳入235个随机对照试验,涉及320首中药处方,平均用药味数13.29味,使用频率前五位的药分别为延胡索、赤芍、当归、蒲公英、丹参;关联规则共得出41对高关联药对,其中包括赤芍-延胡索、莪术-三棱-败酱草等。高频率使用的前30味中药可分为五大类,获取的9个主成分分析结果与系统聚类中的结果一致。结论 本研究采用循证医学和系统聚类分析方法,剖析中医药治疗盆腔炎的用药规律,为临床用药提供参考。
Objective To discuss the medication regularity of traditional Chinese medicine (TCM) in the treatment of pelvic inflammatory disease, and provide new thinking for effective medication in clinical medicine. Methods Keywords combined with free word were used to comprehensively search CNKI, VIP, Wangfang, CBM, PubMed and EMbase, databases and Cochrane library to collect randomized controlled trials of comparative treatment of pelvic inflammatory disease between Chinese and Western drugs. The TCM prescriptions covered in the randomized controlled trial were selected in strict accordance with the standard inclusion and exclusion criteria. Excel was used to statistically analyze the four properties, five flavors, meridian and medication frequency of TCM prescriptions. Then, systematic clustering software was used to carry out correlation, clustering and principal component analysis for the Chinese medicines with high using frequency. Results The study included 235 randomized controlled trial and 320 prescriptions of traditional Chinese medicine were involved, the average number of herbs was 13.29, which Yanhusuo, Chishao, Danggui, Pugongying, Danshen were with top five frequency. A total of 41 drug pairs with high association were obtained by association rules, including Chishao-Yanhusuo, Eshu-Sanleng-Baijiangcao, etc. Thirty traditional Chinese medicine with high using frequency can be divided into 5 categories according to the effect. The obtained results of 9 principal component analysis were consistent with those in the system cluster. Conclusions In this study, evidence-based medicine and systematic cluster analysis were used to analyze the medication regularity of traditional Chinese medicine in the treatment of pelvic inflammatory disease, so as to provide reference for the clinical medication.
前列腺癌作为最常见的男性泌尿系统恶性肿瘤之一,目前常规治疗手段主要为手术、放化疗、内分泌治疗等,但后期并发症、治疗副作用等问题突出,且多转化为去势抵抗性前列腺癌,预后极差。既往研究已然证实,中医药在前列腺癌的治疗中可有效减少复发、减轻症状,提高患者生活质量。本文旨在总结近几年中医药对前列腺癌的研究,为往后的研究与临床治疗提供一些新的思路。
Prostate cancer(PCa) is one of the most common male urinary system malignancies.At present,conventional treatment methods are mainly surgery, radiotherapy and chemotherapy, endocrine therapy,etc.However, late complications, treatment side effects and other problems are prominent, and prostate cancer tends to develop as castration-resistant prostate cancer (CRPC), and the prognosis is very poor. Previous studies have confirmed that Chinese medicine can effectively reduce recurrence incidence, relieve symptoms and improve the quality of life of patients in the treatment of prostate cancer. This article summarizes the research of traditional Chinese medicine on prostate cancer in recent years, and provides some new ideas for future research and clinical treatment.
目的 探讨在待产孕妇中应用中医药辨证护理对促进气血虚弱型足月妊娠孕妇宫颈成熟的临产前护理策略及临床效果。方法 选取中医辨证为气血虚弱型的足月妊娠单胎头位初产妇180例,随机分为对照组即催产素组及常规护理组60例,中医药辨证护理组即在对照组的基础上入院后即给予中药口服加辨证护理60例,空白组即期待观察组及常规护理组60例。观察三组治疗前后宫颈Bishop评分,阴道及宫颈分泌物FFN(胎儿纤连蛋白)定性测定,分娩结局及对母胎的影响。结果 中医药辨证护理组在临产率、阴道分娩率及宫颈评分、FFN测定等方面较对照组及空白组均有差异,P<0.05。结论 对于气血虚弱型足月妊娠在入院后开展中医药辨证护理对临产前宫颈成熟有辅助作用,对于提高顺产率,降低高危分娩促进母儿健康有积极作用,值得推广。
Objective To explore the prenatal care strategy of applying Chinese medicine dialectical care to promoting cervical ripening of full-term pregnant women with qi-blood deficiency and its clinical effect. Methods We chose 180 first-time, full-term pregnant women with single fetus cephalic presentation who were diagnosed as with qi-blood deficiency and then randomly divided them into three groups, 60 in control group with oxytocin and usual care; 60 in group of Chinese medicine dialectical care, which provided oral use of Chinese medicine and dialectical care after those women being admitted to hospital; 60 in blank group with usual observation and care. We did Bishop assessment of neck of uterus before and after treatment in these three groups, conducted qualitative test in FFN (Fetal Fibronectin), the secreta from vagina and neck of uterus, and observed delivery outcome as well as the influence to mother and child. Results Compared with control group and blank group, the group ofChinese medicine dialectical care was outstanding in terms of labor rate, vaginal delivery rate, and FFN test(P<0.05). Conclusion Chinese medicine dialectical care boosts cervical ripening of full-term pregnant women with qi-blood deficiency. It is helpful to increase natural labor rate, reduce high-risk delivery, and promote health of mother and child. Therefore it is worth to be popularized.
